Date: 2017-12-13
Type of information: Nomination
Compound:
Company: Audentes Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 13, 2017, Audentes Therapeutics announced the appointment of Mark A. Goldberg, M.D. to its board of directors. Dr. Goldberg is a rare disease leader who brings over 20 years of experience developing and commercializing products to address serious unmet medical needs. Earlier in his career, Dr. Goldberg served as the Executive Vice President, Global Medical and Regulatory Strategy at Synageva, with responsibility for medical and regulatory affairs. He previously served as Senior Vice President for Clinical Development and Global Therapeutic Group Head for Oncology and Personalized Genetic Health at Genzyme Corporation, where he was responsible for leading clinical development teams for all drugs in development in those therapeutic areas. While at Genzyme he played a central role in the development and approval of multiple innovative rare disease therapeutics, including Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®. Dr. Goldberg is a board-certified medical oncologist and hematologist, holds appointments at Brigham and Women's Hospital and the Dana Farber Cancer Institute, and received his A/B from Harvard College and his M.D. from Harvard Medical School.
Financial terms:
Latest news:
Is general: Yes
